Target engagement and efficacy in disease-modifying trials of synuclein-related disorders

Clicks: 9
ID: 332150
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #425 of 435 articles by views in Brain research

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 435 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Disease-modifying trials in Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) increasingly incorporate fluid and imaging biomarkers to demonstrate target engagement, de-risk subsequent phases of drug development and provide mechanistic evidence of biological activity. Whether biomarker modulation predicts clinical benefit remains unclear. We conducted a PRISMA-compliant review of phase II and III disease-modifying trials (2020-2025) that included at least one biomarker intended to assess target engagement. Twenty-six trials met inclusion criteria (PD=19, MSA=4, DLB=3; n=2,195 participants). Target engagement was reported in 14 of 19 PD trials (12 phase II/2 phase III), 1 of 4 MSA trials, and 2 of 3 DLB trials (all phase II). Concordance between target engagement and clinical improvement was uncommon, as only 8/26 studies (7 phase II/1 phase III) demonstrated both target engagement and statistically significant clinical benefit, and just two of these (both phase II, one in PD and one in MSA) were rigorously controlled with low or moderate risk of bias. Nine trials showed target engagement without clinical benefit, whereas two reported clinical improvement without measurable target engagement. Baseline biomarker-guided patient selection was uncommon and rarely aligned with the compound's mechanism of action. Patient-reported outcomes were widely used but rarely improved. Across recent disease-modifying trials in PD, DLB, and MSA, target engagement was frequently demonstrated, yet clinical benefit rarely followed. These findings question the predictive value of currently used target-engagement biomarkers and highlight the need to biologically align trial populations with the mechanisms targeted by experimental molecular interventions.
Reference Key
openalex_W7221532024 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Carlo Alberto Artusi, Silvia Gallo, Silvia Galli, Domiziana Rinaldi, Michèle Tinazzi, Olivier Rascol, Alberto J. Espay, Margherita Fabbri
Journal Brain research
Year 2026
DOI
10.1093/brain/awag353
URL
https://doi.org/10.1093/brain/awag353
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.